MGC Pharmaceuticals Ltd
ASX:MXC

Watchlist Manager
MGC Pharmaceuticals Ltd Logo
MGC Pharmaceuticals Ltd
ASX:MXC
Watchlist
Price: 0.415 AUD Market Closed
Market Cap: 18.2m AUD

Relative Value

MXC doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of MXC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MXC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
68
vs Industry
11
Median 3Y
13.7
Median 5Y
54.5
Industry
2.7
Forward
4
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-10.5
Industry
21.6
vs History
vs Industry
Median 3Y
-15.8
Median 5Y
-18.3
Industry
16.9
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-29.8
Industry
22.9
vs History
52
vs Industry
4
Median 3Y
13.4
Median 5Y
13.4
Industry
2.3
vs History
69
vs Industry
14
Median 3Y
9.1
Median 5Y
54.7
Industry
3
Forward
2.6
vs History
68
vs Industry
4
Median 3Y
41.5
Median 5Y
108.8
Industry
5.6
vs History
vs Industry
53
Median 3Y
-0.8
Median 5Y
-14.4
Industry
13.4
vs History
vs Industry
51
Median 3Y
-0.8
Median 5Y
-14.4
Industry
16.7
vs History
vs Industry
46
Median 3Y
-10.4
Median 5Y
-18.3
Industry
16.1
vs History
vs Industry
34
Median 3Y
-12.9
Median 5Y
-18
Industry
18.9
vs History
71
vs Industry
44
Median 3Y
1.4
Median 5Y
23.6
Industry
2

Multiples Across Competitors

MXC Competitors Multiples
MGC Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
MGC Pharmaceuticals Ltd
ASX:MXC
18.2m AUD 13.7 -1.1 -0.8 -0.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.5B CHF 4.4 28.8 12.3 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.9 159.4
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.4B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.4 11.4 13.3
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
AU
MGC Pharmaceuticals Ltd
ASX:MXC
Average P/E: 24.9
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.4
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
MGC Pharmaceuticals Ltd
ASX:MXC
Average EV/EBITDA: 440
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
MGC Pharmaceuticals Ltd
ASX:MXC
Average EV/EBIT: 1 883.6
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5